BioSight
Companies
uniQure N.V. logo

QURE

NASDAQAMSTERDAM
uniQure N.V.

uniQure is a biotechnology company developing gene therapy treatments for genetic diseases. Based on the filing excerpt, AMT-130 appears to be a lead candidate undergoing clinical development, with regulatory interactions ongoing regarding a Biologics License Application submission to the FDA. The organization is pursuing research and development across multiple product candidates while working to establish manufacturing and commercialization capabilities.

Price history not yet available for QURE.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar